| http://www.w3.org/ns/prov#value | - CVA21 binds to specific receptor proteins highly expressed on multiple cancer types including melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.Intratumourally administered CAVATAK is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US. Viralytics also plans to commence a Phase
|
